Ianalumab
- Generic Name
- Ianalumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1929549-92-7
- Unique Ingredient Identifier
- ZN2GQ3II96
- Background
Ianalumab is under investigation in clinical trial NCT01930175 (Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris).
- Associated Conditions
- -
- Associated Therapies
- -
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
- First Posted Date
- 2024-12-02
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 316
- Registration Number
- NCT06711887
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT06470048
- Locations
- 🇺🇸
Clinical Res Of W Florida, Clearwater, Florida, United States
🇺🇸Prolato Clinical Research Center, Houston, Texas, United States
🇹🇷Novartis Investigative Site, Istanbul, Turkey
Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases
- Conditions
- Interventions
- First Posted Date
- 2024-05-13
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT06411639
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 550
- Registration Number
- NCT06133972
- Locations
- 🇺🇸
Pinnacle Research Group Llc, Anniston, Alabama, United States
🇺🇸Millennium Clinical Trials, Westlake Village, California, United States
🇺🇸Clinical Res Of W Florida, Clearwater, Florida, United States
A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies
- Conditions
- Interventions
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT05885555
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Cente, Boston, Massachusetts, United States
🇬🇧Novartis Investigative Site, London, United Kingdom
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
- Conditions
- Interventions
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 225
- Registration Number
- NCT05653349
- Locations
- 🇺🇸
Uni of Chi Medi Ctr Hema and Onco, Chicago, Illinois, United States
🇺🇸Parkview Research Center, Fort Wayne, Indiana, United States
🇺🇸Mayo Clinic Rochester, Rochester, Minnesota, United States
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
- Conditions
- Interventions
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 150
- Registration Number
- NCT05653219
- Locations
- 🇺🇸
Yuma Regional Medical Center, Yuma, Arizona, United States
🇺🇸Community Cancer Institute, Clovis, California, United States
🇺🇸Compassionate Care Res Group Inc, Fountain Valley, California, United States
A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia
- Conditions
- Interventions
- First Posted Date
- 2022-12-13
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 90
- Registration Number
- NCT05648968
- Locations
- 🇺🇸
Napa Research, Margate, Florida, United States
🇺🇸Parkview Research Center, Fort Wayne, Indiana, United States
🇺🇸Montefiore Medical Center, Bronx, New York, United States
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
- First Posted Date
- 2022-12-06
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 406
- Registration Number
- NCT05639114
- Locations
- 🇺🇸
Henry Ford Health, Detroit, Michigan, United States
🇺🇸Sahni Rheumatology and Therapy, West Long Branch, New Jersey, United States
🇺🇸NYU Langone Health, Brooklyn, New York, United States
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
- First Posted Date
- 2022-11-22
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 280
- Registration Number
- NCT05624749
- Locations
- 🇺🇸
Washington Univ School Of Medicine, Saint Louis, Missouri, United States
🇺🇸West Tennessee Research Institute, Jackson, Tennessee, United States
🇺🇸Novel Research LLC, Bellaire, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.